Xenetic Biosciences annual working capital
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Xenetic Biosciences Working Capital Growth & History (XBIO)
Xenetic Biosciences's working capital was $7.1M for fiscal 2025.
View full Xenetic Biosciences company overviewXenetic Biosciences annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.1M | $1.4M | +24.39% |
| 2024 | 2024-12-31 | $5.7M | −$3.1M | −35.14% |
| 2023 | 2023-12-31 | $8.8M | −$3.8M | −30.23% |
| 2022 | 2022-12-31 | $12.6M | −$4.7M | −27.29% |
| 2021 | 2021-12-31 | $17.3M | $5.9M | +51.34% |
| 2020 | 2020-12-31 | $11.4M | $1.8M | +18.17% |
| 2019 | 2019-12-31 | $9.7M | $10.1M | — |
| 2018 | 2018-12-31 | −$405,817 | −$4.3M | — |
| 2017 | 2017-12-31 | $3.9M | −$2.5M | −39.11% |
| 2016 | 2016-12-31 | $6.5M | $9.6M | — |
| 2015 | 2015-12-31 | −$3.2M | −$3.2M | — |
| 2014 | 2014-12-31 | $78,490 | −$1.7M | −95.49% |
| 2013 · Dec 31 | 2013-12-31 | $1.7M | −$8.4M | −82.85% |
| 2013 · Aug 31 | 2013-08-31 | −$383,133 | −$310,019 | — |
| 2012 · Dec 31 | 2012-12-31 | $10.1M | — | — |
| 2012 · Aug 31 | 2012-08-31 | −$73,114 | — | — |
Xenetic Biosciences quarterly working capital
As of Aug 31, 2011
Q2.12
Q3.12
Q4.12
Q1.13
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.8M | $1.3M | +29.41% |
| Q1 2026 | 2026-03-31 | $6.6M | $1.8M | +38.00% |
| Q4 2025 | 2025-12-31 | $7.1M | $1.4M | +24.39% |
| Q3 2025 | 2025-09-30 | $4.0M | −$2.1M | −34.26% |
| Q2 2025 | 2025-06-30 | $4.5M | −$2.0M | −30.76% |
| Q1 2025 | 2025-03-31 | $4.8M | −$2.8M | −37.21% |
| Q4 2024 | 2024-12-31 | $5.7M | −$3.1M | −35.14% |
| Q3 2024 | 2024-09-30 | $6.0M | −$4.2M | −40.93% |
| Q2 2024 | 2024-06-30 | $6.4M | −$4.7M | −42.48% |
| Q1 2024 | 2024-03-31 | $7.7M | −$4.4M | −36.25% |
| Q4 2023 | 2023-12-31 | $8.8M | −$3.8M | −30.23% |
| Q3 2023 | 2023-09-30 | $10.2M | −$2.9M | −22.33% |
| Q2 2023 | 2023-06-30 | $11.2M | −$2.9M | −20.74% |
| Q1 2023 | 2023-03-31 | $12.0M | −$3.8M | −24.08% |
| Q4 2022 | 2022-12-31 | $12.6M | −$4.7M | −27.29% |
| Q3 2022 | 2022-09-30 | $13.1M | −$6.3M | −32.60% |
| Q2 2022 | 2022-06-30 | $14.1M | $4.9M | +52.55% |
| Q1 2022 | 2022-03-31 | $15.8M | $5.6M | +54.58% |
| Q4 2021 | 2021-12-31 | $17.3M | $5.9M | +51.34% |
| Q3 2021 | 2021-09-30 | $19.5M | $12.3M | +170.14% |
| Q2 2021 | 2021-06-30 | $9.2M | $912,695 | +10.96% |
| Q1 2021 | 2021-03-31 | $10.2M | $1.1M | +11.64% |
| Q4 2020 | 2020-12-31 | $11.4M | $1.8M | +18.17% |
| Q3 2020 | 2020-09-30 | $7.2M | −$4.0M | −35.82% |
| Q2 2020 | 2020-06-30 | $8.3M | $8.3M | +11622.65% |
| Q1 2020 | 2020-03-31 | $9.2M | $8.0M | +667.14% |
| Q4 2019 | 2019-12-31 | $9.7M | $10.1M | — |
| Q3 2019 | 2019-09-30 | $11.2M | $10.3M | +1057.79% |
| Q2 2019 | 2019-06-30 | $71,046 | −$2.4M | −97.10% |
| Q1 2019 | 2019-03-31 | $1.2M | −$1.3M | −52.88% |
| Q4 2018 | 2018-12-31 | −$405,817 | −$4.3M | — |
| Q3 2018 | 2018-09-30 | $969,435 | $1.1M | — |
| Q2 2018 | 2018-06-30 | $2.4M | $616,257 | +33.68% |
| Q1 2018 | 2018-03-31 | $2.5M | −$1.7M | −39.83% |
| Q4 2017 | 2017-12-31 | $3.9M | −$2.5M | −39.11% |
| Q3 2017 | 2017-09-30 | −$112,231 | $3.6M | — |
| Q2 2017 | 2017-06-30 | $1.8M | $5.2M | — |
| Q1 2017 | 2017-03-31 | $4.2M | $8.9M | — |
| Q4 2016 | 2016-12-31 | $6.5M | $9.6M | — |
| Q3 2016 | 2016-09-30 | −$3.8M | $841,977 | — |
| Q2 2016 | 2016-06-30 | −$3.3M | −$351,295 | — |
| Q1 2016 | 2016-03-31 | −$4.7M | −$3.0M | — |
| Q4 2015 | 2015-12-31 | −$3.2M | −$3.2M | — |
| Q3 2015 | 2015-09-30 | −$4.6M | −$7.9M | — |
| Q2 2015 | 2015-06-30 | −$3.0M | −$9.1M | — |
| Q1 2015 | 2015-03-31 | −$1.7M | −$10.5M | — |
| Q4 2014 | 2014-12-31 | $78,490 | −$1.7M | −95.49% |
| Q3 2014 | 2014-09-30 | $3.3M | — | — |
| Q2 2014 | 2014-06-30 | $6.2M | — | — |
| Q1 2014 · Mar 31 | 2014-03-31 | $8.8M | — | — |
| Q4 2013 · Dec 31 | 2013-12-31 | $1.7M | −$8.4M | −82.85% |
| Q1 2014 · Nov 30 | 2013-11-30 | −$287,312 | −$205,032 | — |
| Q4 2013 · Aug 31 | 2013-08-31 | −$383,133 | −$310,019 | — |
| Q2 2013 | 2013-05-31 | −$70,256 | −$35,211 | — |
| Q1 2013 · Feb 28 | 2013-02-28 | −$61,885 | −$25,385 | — |
| Q4 2012 · Dec 31 | 2012-12-31 | $10.1M | — | — |
| Q1 2013 · Nov 30 | 2012-11-30 | −$82,280 | — | — |
| Q4 2012 · Aug 31 | 2012-08-31 | −$73,114 | −$75,192 | — |
| Q3 2012 | 2012-05-31 | −$35,045 | — | — |
| Q2 2012 | 2012-02-29 | −$36,500 | — | — |
| As of Aug 31, 2011 | 2011-08-31 | $2,078 | — | — |
Xenetic Biosciences working capital trends
Over the last five fiscal years, Xenetic Biosciences's working capital decreased from $11.4M to $7.1M, a change of −$4.4M. The latest reported quarter, Q2 2026, shows $5.8M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xenetic Biosciences source filings ↗